Radionuclide therapy using the radioactive element terbium shows promising potential in treating lymphoma, according to recent experimental results from the Paul Scherrer Institute (PSI) in collaboration with Inselspital – Bern University Hospital.
Elisa Rioja-Blanco and Martin Béhé are jointly conducting research at the Center for Radiopharmaceutical Sciences, part of the PSI Center for Life Sciences. The researchers are now refining this type of therapy in order to carry out clinical trials.
Every year, almost 2,000 people in Switzerland are diagnosed with lymphoma, and about 570 of them die from the disease. Researchers at PSI’s Center for Radiopharmaceutical Sciences are now proposing a new therapy that could soon increase the chances of survival for many of those affected: radioimmunotherapy with the nuclide terbium-161.
“The radioactive isotope terbium-161 is attached to an antibody and injected into the bloodstream of the patient,” explains Martin Béhé from the Center for Radiopharmaceutical Sciences, part of the PSI Center for Life Sciences. This antibody latches onto a structure in the body that is particularly common in lymphoma cells: the CD30 receptor. “This brings the radioactive terbium directly to the site of the tumour to kill the cancer cells with its radioactive radiation.” Healthy organs in the body are spared, on the other hand.
In almost a third of all lymphoma patients, the tumour cells produce the CD30 receptor – in these patients the new treatment could be applied. The same is true of T-cell lymphomas, in which the T-lymphocytes of the immune system become cancerous – a disease that has until now been difficult to treat.
Radionuclide therapy is already well established in clinical practice. Hospitals currently carry out this form of cancer treatment with a different radioactive substance: the nuclide lutetium-177. This is used to treat prostate cancer and tumours arising from hormone-producing cells. Radioactive lutetium decays to produce high-energy, high-velocity electrons, called beta particles, which combat larger tumours effectively.
However, individual tumour cells and small clusters of cancer cells elude treatment with lutetium-177 and can lead to a recurrence of the disease. This makes this form of radionuclide therapy unsuitable for lymphoma. In this type of cancer, some of the tumour cells circulate in the bloodstream rather than existing as a larger, localisable tumour.
Terbium-161 has a decisive advantage over lutetium-177: in addition to beta particles, it also emits conversion and Auger electrons. “This radiation has a range of less than one micrometre, or one thousandth of a millimetre. This is the size of a tumour cell,” explains Martin Béhé. Hence, terbium-161 acts on its immediate surroundings, making it particularly suitable for the targeted treatment of smaller tumours.
“Terbium-161 fires more precise bullets, so to speak,” explains Elisa Rioja-Blanco, also from the Center for Radiopharmaceutical Sciences and first author of the study. Even individual cancer cells in the blood could be eliminated without causing severe side effects. “We can also catch small tumour foci that doctors may not even be aware of at the time.”
The isotope has a half-life of 6.9 days, which means that its effect is halved every 6.9 days. This is an advantage for radionuclide therapy: after manufacturing the drug, it can be transported to a hospital without losing too much of its activity on the way. On the other hand, the radiation level decreases rapidly after treatment within a reasonable period of time.
A powerful weapon against cancer cells
The PSI researchers led by Martin Béhé and Elisa Rioja-Blanco produced the active substance, consisting of terbium-161 and an antibody against the CD30 receptor, themselves at PSI. They then tested it in the laboratory on three types of cancer cells that produce CD30 receptors. They found that – depending on the type of cell – the substance was 2 to 43 times as effective at killing the cancer cells than the analogous substance using lutetium-177. Further experiments have shown that this is because the terbium-based drug caused more severe damage to the DNA in the cancer cell, which the cell itself is unable to repair.
The researchers then tested the drug on mice suffering from cancer. “This shows us where the substance accumulates in the body and whether it actually reaches tumours,” explains Elisa Rioja-Blanco. The substance was indeed preferentially absorbed by the tumour tissue. On average, mice treated with terbium-161 survived twice as long as their counterparts injected with a lutetium-177 drug. Some of the mice even ended up completely cancer-free after the treatment.
On the way to clinical trials
Terbium-161 is already being tested as an anti-cancer drug in several clinical trials – the PSI researchers have now for the first time scrutinised it as a potential treatment for lymphoma. “Our results are a good indication that the substance could also prove to be effective against lymphoma in humans,” says Elisa Rioja-Blanco. Clinical studies will hopefully soon show whether this is indeed the case.
The Lymphoma Challenge, organised by ETH Zurich, is providing financial support for the project. The team has now secured follow-on funding from Innosuisse to further investigate and optimise the drug so that it can be commercialised and tested in humans in the future.
Wildfires near Spokane, Washington, have destroyed at least 700 buildings and forced tens of thousands of people to evacuate. The fires have been burn...
Tehran had made plans to strike sites in Ukraine after Kyiv attacked an Iranian cargo ship in the Caspian Sea, a senior Iranian military adviser has s...
European Commission President Ursula von der Leyen has proposed strengthening the European Union’s external borders and increasing support for Moroc...
U.S. President Donald Trump says Iran has a "last chance" to sign what he described as "a good document", claiming talks are continuing at Tehran's request with backing from Saudi Arabia, the UAE and Qatar.
U.S. President Donald Trump said late on Saturday he would hold off on a fresh attack on Iran as long as a deal could be reached quickly to halt Iran's nuclear ambitions and reopen the Strait of Hormuz.
Indonesian rescue teams are searching for 28 people still unaccounted for, three days after a passenger ferry caught fire off the coast of Madura island.
Two firefighting helicopters collided while battling a major wildfire in Greece on Sunday, killing two crew members as emergency services continued efforts to contain fires fuelled by extreme heat and dry conditions across Europe.
At least eight people were killed in overnight Ukrainian drone strikes across Russia, regional officials said, as Kyiv expanded attacks on infrastructure.
Australia warned on Monday (3 August) of a wider spread of H5N1 bird flu after its first confirmed mass mortality event among seabirds killed about 50 greater crested terns off the coast of South Australia, south of Adelaide.
Cancer patients in Sudan are struggling to access life-saving treatment as soaring medication costs, power shortages and damaged hospital infrastructure deepen the country's healthcare crisis after more than three years of war.
The world risks a resurgence of the HIV epidemic after international funding fell by nearly a fifth last year, according to a new report from UNAIDS, which warned that decades of progress against the disease could be reversed without renewed global support.
A global shift towards healthier diets, more efficient farming and reduced food waste could cut greenhouse gas emissions from agriculture-related land-use change by 85% by 2050, according to a study published last week in the journal Nature.
Venezuelan health authorities have confirmed that three people have died from hantavirus infections, while stressing there is no evidence that the disease is spreading between people in the country.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment